Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms. This partnership establishes a cost-efficient global footprint for clinical pharmacology services,providing an opportunity for both organisations to engage pharmaceutical clients strategically,Biocon said in a statement. Clinigene Chief Operating Officer Abhijit Barve said: "Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development,streamlining processes while maintaining high quality. "Our strategic partnership is designed to deliver this in a very cost-effective manner." The company,however,did not disclose financial details. "With Clinigene's expertise and cost-effective approach .our clients are able to easily structure a program for their compound that delivers high-value value," Spaulding Clinical CEO Randol Spaulding said. Shares of Biocon today closed at Rs 329.20 on the Bombay Stock Exchange,up 2.01 per cent from its previous close.
